Provectus Biopharmaceuticals Inc.
7327 Oak Ridge Highway
Suite B
Knoxville
Tennessee
37931
United States
Tel: 866-594-5999
Website: http://www.pvct.com/
361 articles about Provectus Biopharmaceuticals Inc.
-
Provectus Biopharmaceuticals Announces Exclusive Worldwide License Agreement with University of Miami for Photodynamic Antimicrobial Treatment of Different Eye Infections with Rose Bengal Sodium
3/27/2024
Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) announced today that it has entered into an agreement with the University of Miami (the “University”) for the exclusive worldwide license of the University’s intellectual property related to photodynamic antimicrobial therapy (“PDAT”) for treating bacterial, fungal, and parasitic (acanthamoeba) infections of the eye.
-
Provectus Biopharmaceuticals Announces Notices of Allowance and Award for U.S. Patents of Rose Bengal Sodium in Virology, Pediatric Solid Tumor Cancers, and Vaccines
3/12/2024
Provectus Biopharmaceuticals, Inc. announced that the United States Patent and Trademark Office has allowed patent application 17/212,723, titled “Novel Uses of Halogenated Xanthenes in Oncology and Virology.” The application covers the use of Provectus’s pharmaceutical-grade rose bengal sodium drug substance for the treatment of infectious diseases, such as coronaviruses.
-
Provectus Biopharmaceuticals Announces Acceptance of Cancer Immunotherapy PV-10 Abstract for HNSCC at AACR 2024 Annual Meeting
3/7/2024
Provectus Biopharmaceuticals, Inc. today announced that data from preclinical research on PV-10 (rose bengal sodium) for the treatments of human papillomavirus (“HPV”)-positive and HPV-negative head and neck squamous cell carcinoma.
-
Provectus Biopharmaceuticals Announces Acceptance of Pharmaceutical-Grade Rose Bengal Sodium Abstract for Poster Presentation at 2024 Society for Investigative Dermatology (SID) Annual Meeting
2/29/2024
Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that data from ongoing preclinical research on the topical administration of a formulation of Provectus’s proprietary, pharmaceutical-grade, small molecule, rose bengal sodium (“RBS”) drug substance are being presented at the annual meeting of the Society for Investigative Dermatology (“SID”), to be held May 15-18, 2024 in Dallas, Texas.
-
Provectus Biopharmaceuticals Announces First Quarter 2024 Conference Call
2/15/2024
Provectus Biopharmaceuticals, Inc. announced that it will host a conference call starting at 3 p.m. EST on Thursday, February 22, 2024, to provide Company updates.
-
Provectus Biopharmaceuticals Engages irlabs for Investor Relations Services
2/14/2024
Provectus Biopharmaceuticals, Inc. announced that it has engaged IR Labs, Inc. to develop a comprehensive investor relations and corporate communications program for the Company.
-
Provectus Biopharmaceuticals Announces Notice of Allowance of First U.S. Patent of Rose Bengal Sodium for Use as Anticancer and Antiviral Vaccine Adjuvant
12/18/2023
Provectus (OTCQB: PVCT) today announced that the United States Patent and Trademark Office (USPTO) has allowed patent application 17/488,430, titled “Halogenated Xanthenes as Vaccine Adjuvants.”
-
Provectus Biopharmaceuticals Provides Updated Data on Cancer Immunotherapy PV-10 for Advanced Cutaneous Melanoma
11/15/2023
Provectus (OTCQB: PVCT) today provided updated data from an ongoing Phase 1b/2 clinical trial of investigational cancer immunotherapy PV-10 (rose bengal sodium) in combination with standard of care immune checkpoint blockade (CB) for the treatment of advanced cutaneous melanoma ( NCT02557321 ).
-
Provectus Biopharmaceuticals Provides Updated Data on Cancer Immunotherapy PV-10 for Metastatic Uveal Melanoma
11/13/2023
Provectus (OTCQB: PVCT) today provided updated data from an ongoing Phase 1 clinical trial of investigational cancer immunotherapy PV-10 (rose bengal sodium) for the treatment of uveal melanoma (UM) metastatic to the liver (mUM) ( NCT00986661 ).
-
Provectus Biopharmaceuticals Announces Presentation of Preclinical PV-10 Vaccine Adjuvant Data at Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
11/6/2023
Provectus (OTCQB: PVCT) today announced that preclinical data from ongoing research on the potential use of investigational cancer immunotherapy PV-10 (rose bengal sodium) as an adjuvant in vaccines to help them work better was the subject of a poster presentation at the Society for Immunotherapy of Cancer (SITC) 2023 annual meeting, which was held in San Diego, CA from November 1-5.
-
Provectus Biopharmaceuticals Announces Acceptance of PV-10 Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
8/7/2023
Provectus announced that preclinical data from ongoing research on investigational cancer immunotherapy PV-10 as an immune vaccine adjuvant will be presented on a poster presentation at the Society for Immunotherapy of Cancer 2023 annual meeting to be held in San Diego, CA from November 1-5.
-
Provectus Biopharmaceuticals Announces Acceptance of PV-10 Poster Presentations at Society for Melanoma Research (SMR) 2023 Congress
8/1/2023
Provectus (OTCQB: PVCT) today announced that data from ongoing clinical trials of investigational cancer immunotherapy PV-10 (rose bengal sodium) for the combination therapy treatments of uveal melanoma metastatic to the liver (NCT00986661) and Stage III-IV cutaneous melanoma (NCT02557321) will be presented on two poster presentations at the Society for Melanoma Research (SMR) 2023 Congress (the SMR annual meeting) to be held in Philadelphia, PA.
-
Clinical Catch-Up: October 25-29
11/1/2021
Yet another busy week for clinical trial news. Here’s a look. -
Incidence rates for liver cancer began rising in the mid-1970s, and they are expected to go up through at least 2030. This report aims to give an overview of liver cancer, as well as explore current therapies, drugs in the pipeline and the future treatment landscape for patients and their caregiv...
-
Here’s a look at some of last week’s clinical trial announcements, including some from the American Society of Clinical Oncology Annual Meeting you might have missed.
-
PROVECTUS BIOPHARMACEUTICALS PROVIDES UPDATE ON GI CANCER PROGRAM FOR INVESTIGATIONAL DRUG PV-10
7/31/2018
Ongoing Phase 1 basket study of PV-10 for cancers of the liver expanded to include single-center cohort of metastatic uveal melanoma patients
-
PROVECTUS BIOPHARMACEUTICALS CLINICAL TRIALS UPDATE PROVIDED AT EUROPEAN POST-CHICAGO MELANOMA/SKIN CANCER MEETING
7/10/2018
Provectus announced that a clinical trials update was provided at the 8th European Post-Chicago Melanoma/Skin Cancer Meeting, held in Munich, Germany from June 28-29.
-
Think biotechnology, you probably think cutting-edge development of drugs to treat diseases. Yet in 2007, a U.S. EPA report noted that industrial biotechnology and biobased manufacturing are more efficient, cleaner and make better use of sustainable renewable resources.
-
PROVECTUS BIOPHARMACEUTICALS EXPANDS GLOBAL PATENT PORTFOLIO FOR ACTIVE PHARMACEUTICAL INGREDIENT MANUFACTURE
6/19/2018
Provectus today announced that the Indian Patent Office (IPO) has granted the Company’s patent application for the synthetic process used to produce the active pharmaceutical ingredient (API) in PV-10, which is Provectus’ lead investigational oncology drug.
-
Craig Dees, CEO of Provectus treated the company as "his own personal piggy bank" by submitting hundreds of falsified records to obtain $3.2M for personal expenses